✦ LIBER ✦

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

✍ Scribed by S. Zeuzem; M. Rodríguez-Torres; K. Rajender Reddy; P. Marcellin; M. Diago; A. Craxi; P. Pockros; M. Rizzetto; D. Bernstein; M. L. Shiffman; A. Lin; F. Tatsch; S. Hadziyannis

Book ID: 118738896
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 258 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2012.01624.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

631 ASSESSMENT OF SERUM HCV-RNA AT WEEK

631 ASSESSMENT OF SERUM HCV-RNA AT WEEK 12 POST-TREATMENT IS AS RELEVANT AS WEEK 24 TO PREDICT SVR IN HCV PATIENTS RECEIVING PEGINTERFERON PLUS RIBAVIRIN

✍ M. Martinot-Peignoux; C. Stern; M.P. Ripault; L. Leclere; N. Boyer; P. Marcellin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

480 Total HCV core antigen correlates wi

480 Total HCV core antigen correlates with HCV RNA, and predicts sustained virological response (SVR) to peginterferon alfa 2-A (PEG-IFN) and ribavirin (RIB) therapy in chronic hepatitis C (CHC)

✍ V. Gonzalez; R. Planas; E. Padilla; C. Perez; D. Gimenez; L. Matas; R.M. Morilla 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Factors associated with rapid and early

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population

✍ M. Rodriguez-Torres; M. S. Sulkowski; R. T. Chung; F. M. Hamzeh; D. M. Jensen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

[618] OPTIMAL PRETREATMENT VIRAL LOAD CU

[618] OPTIMAL PRETREATMENT VIRAL LOAD CUT-OFF TO PREDICT TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON o-2b PLUS RIBAVIRIN

✍ M. Martinot-Peignoux; M.P. Ripault; S. Maylin; N. Boyer; N. Giuily; C. Castelnau 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Corrigendum to “Peginterferon alfa-2b pl

Corrigendum to “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3” [J Hepatol 40 (2004) 939–999]

✍ Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 43 KB